The Food and Drug Administration (FDA) has delayed its decision about whether to approve Mannkind Corp.’s Afrezza, an inhaled insulin treatment for diabetes, due to concerns about an increased risk of lung cancer. The delay comes just one week after an advisory panel recommended the approval of the therapy for both type 1 and type 2 diabetes under the condition that the drug company collect long-term data on cancer risks and other potential side effects. Afrezza is a whistle-sized device designed to deliver a fast-acting dose of insulin. It offers a convenient alternative for many diabetic patients who currently have to ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.